SCHEMBL4424740

SCHEMBL4424740

CC(C)(C)c1ccc(C(=O)N2CC3C(CNC(=O)c4[c]ccc(N5CCNC(=O)C5)n4)C3C2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 1/20 0.37
SMN1; SMN2 Q16637 4/20 0.36
ALDH1A1 P00352 2/20 0.36
MAPK1 P28482 1/20 0.36
HPGD P15428 2/20 0.36
BTK Q06187 2/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
HTT P42858 2/20 0.33
LMNA P02545 2/20 0.33
POLB P06746 1/20 0.33
RAB9A P51151 1/20 0.33
NPY5R Q15761 2/20 0.33
GBA1 P04062 1/20 0.33
ALOX15 P16050 1/20 0.33
THRB P10828 1/20 0.33
HSD11B1 P28845 1/20 0.33
ENPP2 Q13822 1/20 0.32
ABL1 P00519 1/20 0.32
BCR P11274 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4415706 0.86 HPGD (0.44) SMN1; SMN2ALDH1A1MAPK1HPGDBTK
SCHEMBL4413362 0.85 GAA (0.43) SMN1; SMN2ALDH1A1BTKHTTLMNA
SCHEMBL4414867 0.85 GBA1 (0.36) SMN1; SMN2ALDH1A1MAPK1HPGDBTK
SCHEMBL4418097 0.83 HRH3 (0.39) SMN1; SMN2ALDH1A1MAPK1BTKMEN1
SCHEMBL4421392 0.83 HPGD (0.41) SMN1; SMN2ALDH1A1MAPK1HPGDMEN1
SCHEMBL4419305 0.83 SMN1; SMN2 (0.35) SMN1; SMN2ALDH1A1MAPK1HPGDBTK
SCHEMBL4425062 0.83 TSHR (0.36) SMN1; SMN2ALDH1A1MAPK1BTKMEN1
SCHEMBL4423656 0.82 BTK (0.39) SMN1; SMN2ALDH1A1BTKHTTLMNA
SCHEMBL4414562 0.82 SMN1; SMN2 (0.36) SMN1; SMN2ALDH1A1MAPK1HPGDBTK
SCHEMBL4414898 0.81 BTK (0.40) SMN1; SMN2ALDH1A1MAPK1BTKLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP claimed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US claimed
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP disclosed
US-7473787-B2 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC (US) 2009-01-06 US disclosed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors SLC6A5, SLC1A5, SLC6A3 HPGDS 2272/4885SMN1; SMN2 4003/4885ALDH1A1 3166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.